insights_auto
Why is DMYD-B up 3,35%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
1,05 SEK
arrow_upward
+3,35%(+0,034) 1D
13-окт., 17:22:00 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
1,03 SEK
High
1,08 SEK
Low
1,01 SEK
Mkt. cap
159,38 млн
Avg. vol.
796,34 миң
Volume
744,90 миң
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 млн
No. of employees
42
Open
1,03 SEK
High
1,08 SEK
Low
1,01 SEK
Mkt. cap
159,38 млн
Avg. vol.
796,34 миң
Volume
744,90 миң
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 млн
No. of employees
42
News stories
From web sources and news partners
Seeking Alpha
·
26 мүнөт мурун
Mentions of inflation have ballooned for tech companies – SoFi (SP500:)
Central Oregon Daily
·
17 мүнөт мурун
S&P 500 flat as chipmakers fall and bank earnings roll in
ChartMill
·
40 мүнөт мурун
What's going on in today's session: S&P500 most active stocks
Bloomberg.com
·
4 саат мурун
S&P 500 Record Rally Meets Risk of Peaking Earnings Growth
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB